IPO
-
-
-
-
-
-
-
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
-
-
-
-
-
-
-
Denali Therapeutics (DNLI) Reports 4Q EPS Loss of $0.74 & First-In-Human Dosing of RIPK1 Inhibitor Clinical Program; Names Peter Klein to Board
-
-
-
-
-
-
-
Denali Therapeutics (DNLI) IPO Opens 20% Higher
-
-
-
-
118,853 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

